Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365
Completed
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2019
Locations: Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona +28 locations
Conditions: Multiple Myeloma
Register for Updates
Study of the Effectiveness of Ozurdex for the Control of Uveitis
NCT02049476
Completed
The main purpose of this study is to evaluate whether or not the dexamethasone pellet (Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid (e.g. prednisone) in the treatment of active sight-threatening, noninfectious intermediate and/or posterior uveitis in which immunosuppressive drug therapy is indicated. Uveitis is an inflammation inside the eye. Uveitis can decrease patients' vision if it is not treated. The dexamethasone pellet is an implant filled with a corticosteroid medici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2019
Locations: The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Uveitis, Intermediate, Uveitis, Posterior
Register for Updates
Corticosteroids for Children With Febrile Urinary Tract Infections
NCT01391793
Completed
In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.
Gender:
ALL
Ages:
Between 2 months and 6 years
Trial Updated:
06/24/2019
Locations: Children's National Medical Center, Washington, District of Columbia +5 locations
Conditions: Acute Urinary Tract Infection, Urinary Tract Infection
Register for Updates
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
NCT02046070
Completed
This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2019
Locations: Not set, Hazard, Kentucky +23 locations
Conditions: Multiple Myeloma
Register for Updates
Steroids in Children Hospitalized With Asthma
NCT02780479
Terminated
Asthma is the most common chronic disease of children. A short (3-5 day) course of a short-acting steroid such as Prednisone or Prednisolone has long been the standard of care for asthma exacerbation. Dexamethasone efficacy in asthma exacerbation has been studied in the outpatient setting and was found to be as effective as Prednisone. Dexamethasone has the advantage of shorter course, more compliance, and more tolerable. This has led many emergency departments to provide a 1-2 dose course of De... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
06/20/2019
Locations: Wolfson Children Hospital, Jacksonville, Florida
Conditions: Asthma, Status Asthmaticus, Wheezes
Register for Updates
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02176213
Completed
This study is being done to learn more about the drug, pomalidomide and to gather data on its safety and side effects when used in combination with commercially available cyclophosphamide and dexamethasone. This combination is considered experimental and has not been approved by the FDA. Pomalidomide is a third generation immunomodulatory (IMiDs) agent, which is a more potent version of thalidomide and lenalidomide drugs that have been approved by the United States Food and Drug Administration... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2019
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Register for Updates
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
NCT01055496
Completed
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin, an investigational product, in adults with CD22-positive non-Hodgkin's lymphoma. The trial will involve two arms. In one arm, subjects will receive chemotherapy regimen R-CVP (rituximab, cyclophosphamide, vincristine and prednisone). In the other arm, subjects will receive R-GDP (rituximab, gemcitabine, cisplatinum and dexamethasone). Subjects in both arms will also rec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2019
Locations: Davis Cancer Pavillion and Shands Medical Plaza, Gainesville, Florida +27 locations
Conditions: Lymphoma, B-Cell
Register for Updates
To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension
NCT03975374
Unknown
The objective of the study is to compare and describe efficacy and safety of Tobradex ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of Blepharoconjuctivitis through clinical parameters
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2019
Locations: Sutphin Drugs, Jamaica, New York
Conditions: Blepharo Conjunctivitis
Register for Updates
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
NCT01159574
Completed
This study is intended to investigate the combination of the combination of dexamethasone (Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) \[ClaPd\] in multiple myeloma patients who have relapsed or refractory disease who have failed prior treatment with lenalidomide when used alone or in combination with corticosteroids. Primary endpoint will be response rate to treatment. Secondary endpoints will include toxicity of the combination, time to maximum response, and time to disea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Weill Cornell Medical College, New York, New York
Conditions: Multiple Myeloma
Register for Updates
A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery
NCT03687931
Completed
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease inflammation inside the eye and are safe after cataract surgery.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/23/2019
Locations: Arizona Eye Center, Chandler, Arizona
Conditions: Inflammation Eye
Register for Updates
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
NCT03069950
Withdrawn
The purpose of this study is to see if patients treated with both regional chemotherapy using the HAI pump and intravenous chemotherapy are able to have their liver tumors removed surgically (resected), versus treatment with only intravenous chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2019
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +4 locations
Conditions: Colorectal Adenocarcinoma Metastatic to the Liver
Register for Updates
Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients
NCT02426723
Completed
This is a Phase 1a/1b, multicenter, open-label, two-part study in subjects with relapsed or refractory MM: * Phase 1a: single agent CWP232291. Dose-finding followed by cohort expansion at the maximum tolerated dose (MTD) or optimal dose as determined by the Safety Review Committee (SRC). * Phase 1b: CWP232291 in combination with lenalidomide and dexamethasone. Dose-finding followed by cohort expansion at the combination therapy MTD or optimal dose as determined by the SRC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2019
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas +3 locations
Conditions: Multiple Myeloma
Register for Updates